## Result Update

26<sup>th</sup> July, 2023

## **SBI Life Insurance**

BFSI



## Steady Performance; VNB Margins to Remain Range Bound

## **Changes in Estimates post Q1FY24**

**FY23E/FY24E: NPE** -3.5%/-5.3%; **PAT** 6.9%/24.9%; **EV** -4.1%/-4.1%

#### **Recommendation Rationale**

- Margins expected to remain range bound VNB Margin moderated from 30.5% in Q4FY23 to 28.8% in Q1FY24 due to an increase in the share of ULIP business from 51.9% in Q4FY23 to 53% in Q1FY24 and lower share of Non-par segment. However, it continues to remain within the guided range. In FY24, the management guided that the margin would be range bound between 28-30%.
- **Growth in APE to be driven by growth across products** While there was pent-up demand in the Non-Par products earlier, it has now normalised. The mix of Non-par products declined in Q1FY24. The management is looking forward to steady growth in Non-par products, contributing ~24%-25% to the product mix. The company reported healthy growth in ULIP as a result of strong capital market activity. Furthermore, protection plans witnessed healthy demand and the management expects the momentum to continue. **Despite a soft Q1FY24, the management remains confident of delivering APE growth of ~20-25% in FY24.**
- Focus on agency channel Structural changes have been made to the agency which will
  drive productivity, even as focus on the banca channel continues. The company has added
  ~14K agents in Q1FY24, taking the total count to ~223K agents and it has devised a strategy
  to develop this channel. Thus, the structural change in the agency business will help the
  company accelerate growth moving forward.

### **Sector Outlook: Positive**

**Company Outlook & Guidance:** We continue to like SBI Life Insurance for its strong VNB margins, healthy cost ratios and robust performance delivery potential.

Current Valuation: 2.3x FY25E EV (Earlier Valuation: 2.7x FY24E EV )

Current TP: Rs 1,535/share (Earlier TP: Rs 1,565 /share)

Recommendation: We maintain our BUY recommendation on the stock.

#### Financial Performance

- The company's AUM reported a robust growth of 21% YoY to Rs 3,283 Bn. SBIL's APE grew 4.5% YoY. VNB margin moderated to 28.8% from 30.1% in Q4FY23, witnessing a contraction of 130bps QoQ mainly due to an increase in ULIP. The cost ratio improved from 11.2% in Q1FY23 to 10.8% in Q1FY24.
- The key persistency ratio of the 13<sup>th</sup> and 26<sup>th</sup> months dropped by 60bps YoY and 260bps YoY respectively. However, the persistency ratio of the 61<sup>st</sup> month improved by 640bps YoY.
- New Business Premium (NBP) grew by 11% to Rs 62.1 Bn in Q1FY24 aided by growth in Single premium business by 18%. In total APE, ULIP's share in the product mix increased. PAT increased by 45% YoY to Rs 3.8 Bn.

## Outlook:

The performance of SBIL has been consistently improving led by growth, margins, cost ratio, and persistency. The company's VNB margin, although fallen QoQ, stands healthy in the industry which is led by improving product mix and operating leverage. SBIL enjoys competitive cost ratios in the industry which help it maintain a superior margin profile. There was a dip in persistency ratios of 13th and 26th, however, no particular product contributed to it and the management will follow up to improve the same. With a healthy VNB margin, the management's focus is to have a balanced product mix between high and low-margin products. With insurance being highly underpenetrated in India, we believe SBIL remains well-placed in the life insurance space to explore the opportunity.

## Valuation & Recommendation:

We remain positive on the stock and maintain a **BUY** rating with a TP of **Rs 1,535/share** (2.3x **FY25EV**), implying an upside potential of 18% from the CMP.

## **Key Financials (Standalone)**

(Rs Bn)	Q1FY24	QoQ (%)	YoY (%)	Axis Est.	Variance
Net Premium Earned	131.1	-34.1	18.7	-	-
Annual Premium equivalent. (APE)	30.3	-33.7	4.5	-	-
Total Expenses	270.6	31.6	499	-	-
PAT	3.8	-51	45	-	-
EPS	3.81	-51	45	-	-

Source: Company, Axis Research

	(CMP as of 25 July, 2023)
CMP (Rs)	1,301
Upside /Downside (%)	18%
High/Low (Rs)	1340/1039
Market cap (Cr)	1,30,176
Avg. daily vol. (6m) Shrs	. 12,75,285
No. of shares (Cr)	100.1

## Shareholding (%)

•	Dec-22	Mar-23	Jun-23
Promoter	55.5	55.5	55.5
FIIs	25.1	25.1	26.2
MFs /UTI	11.3	11.1	10.6
Others	8.2	8.3	7.7

## Financial & Valuations

Y/E Mar (Rs Cr)	FY23	FY24E	FY25E
Net Premium	665.8	799.0	918.8
PAT	17.2	19.2	23.2
EV	460.0	556.6	667.9
VNB (%)	30.5	29.8	29.0
P/EV	2.8	2.3	1.9
EPS	17.2	19.2	23.2
P/E	75.6	67.6	56.0
ROE	14.0	14.3	15.8

### Change in Estimates (%)

Y/E Mar	FY24E	FY25E
NPE	-3.5	-5.3
PAT	6.9	24.9
EV	-4.1	-4.1


# ESG disclosure Score\*\*

Environmental Disclosure	2.4
Social Disclosure Score	30.9
Governance Disclosure	63.6
Total ESG Disclosure	32.3
Sector Average	37.5

Source: Bloomberg, Scale: 0.1-100

\*\*Note: This score measures the amount of ESG data a company reports publicly and does not measure the company's performance on any data point. All scores are based on 2022 disclosures

## Relative performance



Source: Ace Equity, Axis Securities

## CA Bhavya Shah

Research Associate

Email: bhavya1.shah@axissecurities.in

## Dnyanada Vaidya

Research Analyst

Email: dnyanada.vaidya@axissecurities.in



## **Key Risks to our Estimates and TP**

Changes in the interest rates would adversely impact certain products offered by the company.

## Change in Estimates

(Rs Bn)

	Re	vised	Old		% Change	
	FY24E	FY25E	FY24E	FY25E	FY24E	FY25E
NPE	799.0	918.8	828.2	970.7	-3.5	-5.3
PAT	19.2	23.2	18.0	18.6	6.9	24.9
EV	556.6	667.9	580.2	696.3	-4.1	-4.1
EPS	19.2	23.2	18.0	18.6	6.9	24.9



Results Review (Rs Mn)

					•
Y/E March	Q1FY24	Q1FY23	% YoY	Q4FY23	% QoQ
First Year Premium	26,374	25,704	2.6	40,896	-35.5
Renewal Premium	73,480	57,577	27.6	1,19,370	-38.4
Single Premium	35,697	30,210	18.2	39,869	-10.5
Premium Earned	1,35,551	1,13,491	19.4	2,00,136	-32.3
Premium on reinsurance ceded	4,506	3,131	43.9	1,167	286.2
Net premium earned	1,31,045	1,10,360	18.7	1,98,969	-34.1
Investment Income	1,45,789	-62,299	-334.0	11,861	1129.1
Other income	86	111	-22.8	149	-42.3
Total income	2,76,920	48,172	474.9	2,10,979	31.3
Commission paid	5,212	5,076	2.7	8,714	-40.2
Operating & other expenses	9,173	9,360	-2.0	9,586	-4.3
Claim/benefit paid	71,034	51,717	37.4	91,232	-22.1
Change in actuarial liability	1,85,197	-20,988	-982.4	96,043	92.8
Total expenses	2,70,615	45,165	499.2	2,05,575	31.6
Profit before tax	3,897	3,008	29.6	7,936	-50.9
Тах	87	380	-77.1	167	-48.0
Profit after tax	3,810	2,628	45.0	7,769	-51.0
Annualized premium equivalent (APE)	30,300	29,000	4.5	45,700	-33.7
VNB Margin (%)	28.8	30.4	4.5	30.1	-33.7
AUM (Bn)	3,282.8	2,623.5	25.1	3,073.0	6.8
Product mix (%) Total APE					
Par	7.0	5.9		6.6	
Non Par	19.0	28.3		22.8	
ULIP	53.0	46.9		51.9	
Individual Savings	79.0	81.0		81.3	
Group Savings	5.0	5.5		3.3	
Individual Protection	7.0	6.9		6.0	
Group Protection	5.0	4.1		5.5	
Channel mix (%) Total APE YTD					
Bancassurance	65	63		64	
Agency	25	26		26	
Others	10	11		10	
Persistency ratios (%)					
13th month	85.00	85.61		85.5	
25th month	76.10	78.72		75.6	
37th month	74.80	72.2		74.5	
49th month	70.40	70.32		70.3	
61st month	56.70	50.26		55.6	
Operational ratios (%)					
Commission Ratio	4	4.6		4.5	
Total Expense Ratio	10.8	11.2		9.6	
Solvency Ratio	2.15	221		2.15	



# Financials (Standalone)

## Policy Holders Account (Rs Bn)

Y/E March	FY22	FY23P	FY24E	FY25E
Gross Premium	587.5	673.2	799.1	927.7
First-year premium	129.4	152.0	190.2	218.8
Renewal Premium	333	377.3	433.9	498.9
Single Premium	125.1	143.9	175.0	210.0
Net Premium (net of reinsurance)	584.3	665.8	799.0	918.8
Income from investments	235.7	132.6	312.7	342.7
Other income	0.4	0.5	0.5	0.5
Total income	830.3	798.9	1112.2	1262.0
Commission	20.8	29.4	32.3	37.1
Operating Expenses	29.7	34.1	40.9	49.1
Operating Profit	779.7	735.4	1038.9	1175.8
Net benefits paid	313.4	302.9	455.4	535.1
Change in reserves	437.6	410.0	558.6	611.9
Provision for tax	1.3	1.5	6.3	6.3
Surplus/Deficit after Tax	27.4	21.1	18.6	22.4
Shareholders Account	17.3	27.1	21.4	25.1
Transfer from the policyholder's account	9.8	7.9	9.9	10.4
Income from investments	0.1	0.0	0.1	0.1
Other income	27.2	35.0	31.4	35.6
Total income	1.6	0.4	1.8	2.0
Ex-insurance expenses	9.8	17.1	9.6	9.4
Contribution to Policyholders Account	15.6	17.6	20.0	24.2
Profit before tax	0.5	0.4	0.8	1.0
Tax	15.1	17.2	19.2	23.2
Profit after tax	17.3	27.1	21.4	25.1




Ratio Analysis (%)

FY22	FY23P	FY24E	FY25E
23.4	16	19	14.5
17.4	13.9	20.0	15.0
24.9	17.0	19.0	15.5
21.1	15.0	26.4	20.0
4.1	13.9	11.8	20.8
15.1	17.2	19.2	23.2
116.2	130.2	150.5	173.7
396.3	460.0	556.6	667.9
2	2.6	3.0	3.3
0.2	0.2	0.2	0.2
13.2	15.1	15.6	14.0
3.3	2.8	2.3	1.9
86.2	75.6	67.6	56.0
26.1	30.5	29.8	29.0
20.6	22.9	21.6	20.8
19.3	16.8	19.8	19.4
13.7	14.0	14.3	15.8
3.6	4.5	4.4	4.4
5.1	5.1	5.2	5.1
	23.4 17.4 24.9 21.1 4.1 15.1 116.2 396.3 2 0.2 13.2 3.3 86.2 26.1 20.6 19.3 13.7 3.6	23.4 16 17.4 13.9 24.9 17.0 21.1 15.0 4.1 13.9  15.1 17.2 116.2 130.2 396.3 460.0 2 2.6 0.2 0.2 13.2 15.1 3.3 2.8 86.2 75.6  26.1 30.5 20.6 22.9 19.3 16.8 13.7 14.0 3.6 4.5	23.4     16     19       17.4     13.9     20.0       24.9     17.0     19.0       21.1     15.0     26.4       4.1     13.9     11.8       15.1     17.2     19.2       116.2     130.2     150.5       396.3     460.0     556.6       2     2.6     3.0       0.2     0.2     0.2       13.2     15.1     15.6       3.3     2.8     2.3       86.2     75.6     67.6       26.1     30.5     29.8       20.6     22.9     21.6       19.3     16.8     19.8       13.7     14.0     14.3       3.6     4.5     4.4



# **SBI Life Insurance Price Chart and Recommendation History**



Date	Reco	TP	Research
30-Jan-20	BUY	1,145	Company Update
06-May-20	Hold	779	Result Update
22-Jul-20	BUY	996	Result Update
27-Jul-20	BUY	996	Pick of the week
26-Oct-20	BUY	998	Result Update
25-Jan-21	BUY	1,076	Result Update
15-Feb-21	BUY	1,011	Pick of the week
26-Apr-21	BUY	1,035	Pick of the week
04-May-21	BUY	1,150	Result Update
27-Jul-21	BUY	1,290	Result Update
28-Oct-21	BUY	1,425	Result Update
24-Jan-22	BUY	1,530	Result Update
29-Apr-22	BUY	1,530	Result Update
29-Jul-22	BUY	1,540	Result Update
25-Oct-22	BUY	1,540	Result Update
23-Jan-23	BUY	1,565	Result Update
26-Jul-23	BUY	1,535	Result Update
_			

Source: Axis Securities



## **About the Analyst**



Associate: CA Bhavya Shah

Contact Details: bhavya1.shah@axissecurities.in

Sector: BFSI

Analyst Bio: Bhavya Shah is Chartered Accountant and CFA level 2 cleared with over one year of research experience in the Banking/NBFC Industry.

## **About the Analyst**



Analyst: Dnyanada Vaidya

Contact Details: dnyanada.vaidya@axissecurites.in

Sector: BFSI

Analyst Bio: Dnyanada Vaidya is M.M.S (Finance) with over 6 years of research experience in the Banking/NBFC sector.

#### Disclosures:

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Axis Securities Ltd. (ASL) is a SEBI Registered Research Analyst having registration no. INH000000297. ASL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. ASL is a subsidiary company of Axis Bank Ltd. Axis Bank Ltd. is a listed public company and one of India's largest private sector bank and has its various subsidiaries engaged in businesses of Asset management, NBFC, Merchant Banking, Trusteeship, Venture Capital, Stock Broking, the details in respect of which are available on www.axisbank.com.

ASL is registered with the Securities & Exchange Board of India (SEBI) for its stock broking & Depository participant business activities and with the Association of Mutual Funds of India (AMFI) for distribution of financial products and also registered with IRDA as a corporate agent for insurance business activity.

ASL has no material adverse disciplinary history as on the date of publication of this report.

I/We, CA Bhavya Shah, author/s and the name/s subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect my/our views about the subject issuer(s) or securities. I/We (Research Analyst) also certify that no part of my/our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. I/we or my/our relative or ASL does not have any financial interest in the subject company. Also I/we or my/our relative or ASL or its Associates may have beneficial ownership of 1% or more in the subject company at the end of the month immediately preceding the date of publication of the Research Report. Since associates of ASL are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this report. I/we or my/our relative or ASL or its associate does not have any material conflict of interest. I/we have not served as director / officer, etc. in the subject company in the last 12-month period. Any holding in stock – No

5. ASL has not received any compensation from the subject company in the past twelve months. ASL has not been engaged in market making activity for the subject company.

In the last 12-month period ending on the last day of the month immediately preceding the date of publication of this research report, ASL or any of its associates may have:

Received compensation for investment banking, merchant banking or stock broking services or for any other services from the subject company of this research report and / or; Managed or co-managed public offering of the securities from the subject company of this research report and / or; Received compensation for products or services other than investment banking, merchant banking or stock broking services from the subject company of this research report; ASL or any of its associates have not received compensation or other benefits from the subject company of this research report or any other third-party in connection with this report.

## Terms & Conditions:

This report has been prepared by ASL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ASL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ASL will not treat recipients as customers by virtue of their receiving this report.



	DEFINITION OF RATINGS				
Ratings	Expected absolute returns over 12-18 months				
BUY	More than 10%				
HOLD	Between 10% and -10%				
SELL	Less than -10%				
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning valuation and recommendation				
UNDER REVIEW	We will revisit our recommendation, valuation and estimates on the stock following recent events				
NO STANCE	We do not have any forward looking estimates, valuation or recommendation for the stock				

#### Disclaimer:

Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to the recipient's specific circumstances. The securities and strategies discussed and opinions expressed, if any, in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

This report may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this report should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this report (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. Certain transactions, including those involving futures, options and other derivatives as well as non-investment grade securities involve substantial risk and are not suitable for all investors. ASL, its directors, analysts or employees do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on basis of this report, including but not restricted to, fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc. Past performance is not necessarily a guide to future performance. Investors are advice necessarily a guide to future performance. Investors are advice necessarily a guide to future performance. Investors are advice necessarily and the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ASL and its affiliated companies, their directors and employees may; (a) from time to time, have long or short position(s) in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities or earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or investment banker, lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting this document.

ASL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that ASL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. ASL may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report. The Research reports are also available & published on AxisDirect website.

Neither this report nor any copy of it may be taken or transmitted into the United State (to U.S. Persons), Canada, or Japan or distributed, directly or indirectly, in the United States or Canada or distributed or redistributed in Japan or to any resident thereof. If this report is inadvertently sent or has reached any individual in such country, especially, USA, the same may be ignored and brought to the attention of the sender. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ASL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors.

The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. The Company reserves the right to make modifications and alternations to this document as may be required from time to time without any prior notice. The views expressed are those of the analyst(s) and the Company may or may not subscribe to all the views expressed therein.

## Copyright in this document vests with Axis Securities Limited.

Axis Securities Limited, SEBI Single Reg. No.- NSE, BSE & MSEI – INZ000161633, ARN No. 64610, CDSL-IN-DP-CDSL-693-2013, SEBI-Research Analyst Reg. No. INH 000000297, SEBI Portfolio Manager Reg. No.- INP000000654, Main/Dealing off.- 1st Floor, I-Rise Building, Q Parc, Loma Park, Thane, Ghansoli, Navi Mumbai-400701, Regd. off.- Axis House,8th Floor, Wadia International Centre, PandurangBudhkar Marg, Worli, Mumbai – 400 025. Compliance Officer: AnandShaha, Email: compliance.officer@axisdirect.in, Tel No: 022-49212706